ExpertREACT: New US vaccine policy - lasting impact
Published February 2026
US vaccine policy has broken with the past, triggering a once‑in‑a‑generation shake‑up in recommendations, governance, funding and liability that is reshaping the US vaccine market.
In January 2026, new HHS leadership oversaw an overhaul of the federal childhood immunisation schedule, with CDC removing universal recommendations for six diseases — COVID‑19, rotavirus, hepatitis A, hepatitis B, influenza and meningococcal — reducing the routine schedule from 17 to 11 vaccines. Other significant policy changes and governance reforms are in motion, but not all US states are aligned, embedding a partisan split into the vaccine system. Together, these shifts are altering demand, coverage, financing and the balance of federal versus state authority.
The new environment has triggered a sharp contraction in private investment in vaccine innovation. mRNA vaccine venture financing has fallen by 82%, from $510M in 2023 to about $90M in 2025 year‑to‑date (1), and investors are increasingly reallocating capital to vaccine and platform developers headquartered outside the US. Although the global vaccine market across the nine major Western producers declined only modestly from $55.2 bn in 2024 to $50.9 bn in 2025 (2), the medium‑term impact of US policy on manufacturers’ revenue mix, R&D priorities and risk disclosures is still unfolding. Manufacturers should also plan for a contested legal landscape around vaccine liability and reassess their exposure to US policy risk.
Lasting impact is a new VacZine Analytics expert briefing examining the commercial and strategic consequences of US federal vaccine policy changes since January 2025. Drawing on VacZine Analytics’ secondary research, manufacturer financial disclosures, epidemiological surveillance data and policy analysis, it provides a structured, evidence‑based assessment of what has changed, what it means for the market, and what can and cannot realistically be reversed.
This ExpertREACT product is designed for professionals across the vaccine industry who must translate a fast‑moving, complex policy environment into concrete portfolio, investment and market access decisions.
THIS PRODUCT IS A SUMMARY PRESENTATION (~ 75 slides, .pdf) + MS Excel Workbook(s)
Photo credit: digitale.de (Unsplash)
(1) Pharmaceutical Technology. (2025, Oct 6). Venture financing for mRNA-based vaccines declines 82% in 2025.
(2) VacZine Analytics internal figures
This analysis leads with human oversight. AI tools have been used in the search stage of the project
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
